Emergent BioSolutions closes $100M ABL credit facility, reports $150M cash balance

Emergent BioSolutions Inc.

New asset-based revolving loan facility of up to $100M, maturing September 2029.
Cash balance of approximately $150M as of September 30, 2024.
ABL facility undrawn at closing; provides additional liquidity for transformation plan.
Facility follows prior $250M term loan refinancing with Oak Hill Advisors in September 2024.

item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.